![Jørgen Buus Lassen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jørgen Buus Lassen
Directeur/Membre du Conseil chez Effector A/S
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Michele Garufi | M | 70 | 28 ans | |
Gavin M. Spencer | M | 53 | 19 ans | |
Jean-François Labbé | M | 73 | 14 ans | |
Jørgen Hansen | M | 64 | 35 ans | |
Erich Mohr | M | 70 |
Collegium Internationale Neuro-Psychopharmacologicum
| - |
Anthony G. Phillips | M | - |
Collegium Internationale Neuro-Psychopharmacologicum
| - |
Salomon Z. Langer | M | - |
Collegium Internationale Neuro-Psychopharmacologicum
| - |
Peter Andersen | M | 67 |
Collegium Internationale Neuro-Psychopharmacologicum
| - |
Sandrine Gestin | F | 56 | 25 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jørgen Drejer | M | 69 |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 23 ans |
Allan Andersen | M | 79 | 30 ans | |
Teit Eliot Johansen | M | - |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 5 ans |
Lars Siim Madsen | M | 53 | 9 ans | |
Thomas Hofman-Bang | M | 60 | 5 ans | |
Finn Eggert Sørensen | M | 70 | - | |
Flemming Heise Pedersen | M | 59 | 10 ans | |
Alex Haahr Gouliaev | M | 58 | 5 ans | |
Lars Ulrik Wahlberg | M | - |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | - |
Philippe Masquida | M | 62 | 4 ans | |
Torbjørn Bjerke | M | 61 | 7 ans | |
Morten Henrik Nielsen | M | 61 | 24 ans | |
Piero del Soldato | M | - | 8 ans | |
Vaughn M. Kailian | M | 79 | 13 ans | |
Birgit Stattin Norinder | F | 75 | 7 ans | |
Torben Skov | M | 57 | - | |
Palle Christophersen | M | 66 | 21 ans | |
Dieter H. Meier | M | 69 | - | |
Mads Peder Gersdorff Korsgaard | M | 53 | 4 ans | |
Jacques Djian | M | - | - | |
Bengt Ingemar Samuelsson | M | 90 | 15 ans | |
Bent Frandsen | M | - |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 ans |
Sanjiv Sharma | M | 68 | 3 ans | |
Francois Ducret | M | - | - | |
Stephane Nicolas | M | 55 | - | |
Staffan Strömberg | M | 57 | 4 ans | |
Emmanuelle Pierry | F | - | 22 ans | |
Philip Kusk | M | - |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 ans |
Gerald W. St. Peter | M | 57 | - | |
Bent Moltved | M | - |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 ans |
Damian Marron | M | 62 | 6 ans | |
Eric Castaldi | M | 59 | 16 ans | |
Pascal Pfister | M | 66 | 5 ans | |
Mette Agger | F | 59 | 4 ans | |
Peter Samuel Wulff | M | 71 | 8 ans | |
Mats Gunnar Pettersson | M | 78 |
NsGene A/S
![]() NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 4 ans |
Frank Waetjen | M | 72 | - | |
Göran Albert Ando | M | 75 | 7 ans | |
Elizabeth Marie Robinson | M | - | - | |
Vicente J. Anido | M | 71 | 1 ans | |
Dan Peters | M | 63 | 11 ans | |
Frank Baldino | M | 71 | 9 ans | |
Jean-Luc Bélingard | M | 74 | 9 ans | |
Rie Schultz Hansen | M | - | 10 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Danemark | 25 | 47,17% |
France | 24 | 45,28% |
Royaume-Uni | 4 | 7,55% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jørgen Buus Lassen
- Réseau Personnel